STAT6 expression in glioblastoma promotes invasive growth

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Merk, Barbara C ^a   Owens, Jennifer L ^a   Lopes, Maria Beatriz S ^a   Silva, Corinne M ^b   Hussaini, Isa M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; INTERSTITIAL COLLAGENASE; SHORT HAIRPIN RNA; STAT6 PROTEIN; THYMIDINE; TRITIUM; UROKINASE; EPIDERMAL GROWTH FACTOR; SMALL INTERFERING RNA; TYROSINE;

ARTICLE; ASTROCYTE; ASTROCYTOMA; BRAIN TISSUE; CANCER CELL CULTURE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CANCER TISSUE; CELL ASSAY; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; GENE EXPRESSION; GENE SILENCING; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MOLECULAR CLONING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STAINING; SURVIVAL TIME; TISSUE MICROARRAY; UPREGULATION; WESTERN BLOTTING; BRAIN TUMOR; DRUG EFFECT; FACTUAL DATABASE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; PATHOPHYSIOLOGY; PHOSPHORYLATION; SURVIVAL; TUMOR CELL LINE;

ASTROCYTOMA; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DATABASES, FACTUAL; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLIOBLASTOMA; GLIOMA; HUMANS; NEOPLASM INVASIVENESS; PHOSPHORYLATION; RNA, SMALL INTERFERING; STAT6 TRANSCRIPTION FACTOR; SURVIVAL ANALYSIS; TYROSINE;

EID: 79956227340     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-184     Document Type: Article

References (76)

1. National Cancer Institute REMBRANDT home page. 2005, Accessed 2010 October 1st, National Cancer Institute., http://rembrandt.nci.nih.gov
2. Kleihues P, Burger PC, Aldape KD, Brat DJ, Biernat W, Bigner DD, Nakazato Y, Plate KH, Giangespero F, von Deimling A, Ohgaki H, Cavenee WK. WHO Classification of Tumors of the Central Nervous System 2007, 33-49. IARC Press: Lyon, Louis DN, Ohgaki H, Wiestler OD, Cavanee WK.
3. Wheeler CJ, Black KL, Liu G, Mazer M, Zhang X, Pepkowitz S, Goldfinger D, Ng H, Irvin D, Yu JS. Vaccination Elicits Correlated Immune and Clinical Responses in Glioblastoma Multiforme Patients. Cancer Research 2008, 68:5955-5964. 10.1158/0008-5472.CAN-07-5973, 18632651.
4. Barcellos-Hoff MH, Newcomb EW, Zagzag D, Narayana A. Therapeutic targets in malignant glioblastoma microenvironment. Semin.Radiat.Oncol 2009, 19:163-170. 10.1016/j.semradonc.2009.02.004, 19464631.
5. Reardon DA, Wen PY. Therapeutic Advances in the Treatment of Glioblastoma: Rationale and Potential Role of Targeted Agents. The Oncologist 2006, 11:152-164. 10.1634/theoncologist.11-2-152, 16476836.
6. Shin-ei N, El-Jawahri A, Patel D, Lautenschlaeger T, Siedow M, Chakravarti A. Molecular Advances of Brain Tumors in Ratiation Oncology. Seminars in Radiation Oncology 2009, 19:171-178. 10.1016/j.semradonc.2009.02.005, 19464632.
7. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996. 10.1056/NEJMoa043330, 15758009.
8. Haura EB, Zheng Z, Song L, Cantor A, Bepler G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin.Cancer Res 2005, 11:8288-8294. 10.1158/1078-0432.CCR-05-0827, 16322287.
9. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000, 19:2474-2488. 10.1038/sj.onc.1203527, 10851046.
10. Grandis JR, Pietenpol JA, Greenberger JS, Pelroy RA, Mohla S. Head and neck cancer: meeting summary and research opportunities. Cancer Res 2004, 64:8126-8129. 10.1158/0008-5472.CAN-04-2445, 15520225.
11. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin.Cancer Res 2002, 8:945-954.
12. Atreya R, Neurath MF. Signaling molecules: the pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer. Curr Drug Targets 2008, 9:369-74. 10.2174/138945008784221116, 18473764.
13. Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, Baus D, Kaufmann R, Huber LA, Zatloukal K, Beug H, Ohlschlager P, Schutz A, Halbhuber KJ, Friedrich. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 2005, 7:545-555. 10.1593/neo.04571, 1501283, 16036105.
14. Migone TS, Lin JX, Cereseto A, Mulloy JC, O'Shea JJ, Franchini G, Leonard WJ. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 1995, 269:79081.
15. Zhang Q, Nowak I, Vonderheid EC, Rook AH, Kadin ME, Nowell PC. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci 1996, 93:9148-9153. 10.1073/pnas.93.17.9148, 38610, 8799169.
16. Schaefer LK, Ren Z, Fuller GN, Schaefer TS. Constitutive activation of Stat3alpha in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). Oncogene 2002, 27:2058-65.
17. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004, 102:37-46. 10.1016/j.pharmthera.2004.01.002, 15056497.
18. Konnikova L, Kotecki M, Kruger MM, Cochran BH. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer 2003, 3:23. 10.1186/1471-2407-3-23, 212316, 13678425.
19. Liang QC, Xiong H, Zhao ZW, Jia D, Li WX, Qin HZ, Deng JP, Gao L, Zhang H, Gao GD. Inhibition of transcription factor STAT5b suppresses proliferation, induces G1 cell cycle arrest and reduces tumor cell invasion in human glioblastoma multiforme cells. Cancer Letters 2009, 273:164-171. 10.1016/j.canlet.2008.08.011, 18793823.
20. Park OK, Schaefer TS, Nathans D. In vitro activation of Stat3 by epidermal growth factor receptor kinase. Proc Natl Acad Sci 1996, 93:13704-8. 10.1073/pnas.93.24.13704, 19397, 8942998.
21. Decker T, Kovarik P. Transcription factor activity of STAT proteins: structural requirements and regulation by phosphorylation and interacting proteins. Cellular and Molecular Life Sciences 1999, 55:1535-1546. 10.1007/s000180050393, 10526571.
22. Mui A. The role of STATs in proliferation, differentiation, and apoptosis. Cellular and Molecular Life Sciences 1999, 55:1547-1558. 10.1007/s000180050394, 10526572.
23. Grad JM, Zeng XR, Boise LH. Regulation of Bcl-xL: a little bit of this and a little bit of STAT. Curr Opin Oncol 2000, 12:543-9. 10.1097/00001622-200011000-00006, 11085453.
24. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE. Stat3 as an oncogene. Cell 1999, 6:295-303.
25. deGroot RP, Raaijmakers JA, Lammers JW, Koenderman L. STAT5-Dependent CyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells. Mol Cell Biol Res Commun 2000, 3:299-305. 10.1006/mcbr.2000.0231, 10964754.
26. Dang CV, Resar LM, Emison E, Kim S, Li Q, Prescott JE, Wonsey D, Zeller K. Function of the c-Myc Oncogenic Transcription Factor. Experimental Cell Research 1999, 253:63-77. 10.1006/excr.1999.4686, 10579912.
27. Kiuchi N, Nakajima K, Ichiba M, Fukada T, Narimatsu M, Mizuno K, Hibi M, Hirano T. STAT3 is required for the gp130-mediated full activation of the c-myc gene. J exp Med 1999, 189:63-73. 10.1084/jem.189.1.63, 1887683, 9874564.
28. Ni Z, Lou W, Lee SO, Dhir R, DeMiguel F, Grandis JR, Gao AC. Selective activation of members of the signal transducers and activators of transcription family in prostate carcinoma. J Urol 2002, 167:1859-1862. 10.1016/S0022-5347(05)65249-4, 11912448.
29. Li BH, Yang XZ, Li PD, Yuan Q, Liu XH, Yuan J, Zhang WJ. IL-4/Stat6 activities correlate with apoptosis and metastasis in colon cancer cells. Biochemical and Biophysical Research Communications 2008, 369:554-560. 10.1016/j.bbrc.2008.02.052, 18294957.
30. Benekli M, Baer MR, Baumann H, Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood 2003, 101:2940-2954. 10.1182/blood-2002-04-1204, 12480704.
31. Skinnider BF, Elia AJ, Gascoyne RD, Patterson B, Trumper L, Kapp U, Mak TW. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2002, 99:618-626. 10.1182/blood.V99.2.618, 11781246.
32. Guiter C, Dusanter-Fourt I, Copie-Bergman C, Boulland ML, Le Gouvello S, Gaulard P, Leroy K, Castellano F. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood 2004, 104:543-549. 10.1182/blood-2003-10-3545, 15044251.
33. Melzner I, Bucur AJ, Bruderlein S, Dorsch K, Hasel C, Barth TF, Leithauser F, Moller P. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 2005, 105:2535-2542. 10.1182/blood-2004-09-3701, 15572583.
34. Bruns HA, Kaplan MH. The role of constitutively active Stat6 in leukemia and lymphoma. Critical Reviews in Oncology/Hematology 2006, 57:245-253. 10.1016/j.critrevonc.2005.08.005, 16213149.
35. Zhang M, Zhou Y, Zhang W, Zhang X, Pan Q, Ji XM, Luo ZG, Wu JP. Apoptosis induced by short hairpin RNA-mediated STAT6 gene silencing in human colon cancer cells. Chinese Medical Journal 2006, 119:801-808.
36. Hussaini IM, Karns LR, Vinton G, Carpenter JE, Redpath GT, Sando JJ. Phorbol 12-myristate 13-acetate induces protein kinase ceta-specific proliferative response in astrocytic tumor cells. J.Biol.Chem 2000, 275:22348-22354. 10.1074/jbc.M003203200, 10806212.
37. Amos S, Mut M, diPierro CG, Carpenter JE, Xiao A, Kohutek ZA, Redpath GT, Zhao Y, Wang J, Shaffrey ME, Hussaini IM. Protein kinase C-alpha-mediated regulation of low-density lipoprotein receptor related protein and urokinase increases astrocytoma invasion. Cancer Research 2007, 67:10241-10251. 10.1158/0008-5472.CAN-07-0030, 2386949, 17974965.
38. Gallagher J, Howlin J, McCarthy C, Murphy EP, Bresnihan B, FitzGerald O, Godson C, Brady HR, Martin F. Identification of Naf1/ABIN-1 among TNF-alpha-induced expressed genes in human synoviocytes using oligonucleaotide microarrays. FEBS Lett 2003, 551:8-12. 10.1016/S0014-5793(03)00823-8, 12965196.
39. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection. Proc Natl Acad Sci 2001,
40. Brantley EC, Benveniste EN. Signal Transducer and Activator of Transcription-3: A Molecular Hub for Signaling Pathways in Gliomas. Mol Cancer Res 2008, 6:675-684. 10.1158/1541-7786.MCR-07-2180, 18505913.
41. Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, Kondo S, Priebe W, Kondo Y. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2006, 26:2435-2444.
42. Gu J, Li G, Sun T, Su Y, Zhang X, Shen J, Tian Z, Zhang J. Blockage of the STAT3 signaling pathway with a decoy oligonucleotide suppresses growth of human malignant glioma cells. J Neurooncol 2008, 89:9-17. 10.1007/s11060-008-9590-9, 18415045.
43. Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, Priebe W, Heimberger AB. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Research 2007, 67:9630-9636. 10.1158/0008-5472.CAN-07-1243, 17942891.
44. Rahaman SO, Sharma P, Harbor PC, Aman MJ, Vogelbaum MA, Haque SJ. IL-13Rα2, a Decoy Receptor for IL-13 Acts As an Inhibitor of IL-4-dependent Signal Transduction in Glioblastoma Cells. Cancer Research 2002, 62:1103-1109.
45. Darnell JE. STATs and Gene Regulation. Science 1997, 277:1630-1635. 10.1126/science.277.5332.1630, 9287210.
46. Stark GR. How cells respond to interferons revisited: From early history to current complexity. Cytokine Growth Factor Rev 2007, 18:419-423. 10.1016/j.cytogfr.2007.06.013, 2081984, 17683974.
47. Heim MH. The Jak-Stat pathway: cytokine signaling from the receptor to the nucleus. J Recept Signal Transduct Res 1999, 19:75-120. 10.3109/10799899909036638, 10071751.
48. Liu KD, Gaffen SL, Goldsmith MA. JAK/STAT signaling by cytokine receptors. Current Opinion in Immunology 1998, 10:271-278. 10.1016/S0952-7915(98)80165-9, 9638363.
49. Ihle JM. The Stat family in cytokine signaling. Current Opinion in Cell Biology 2001, 13:211-217. 10.1016/S0955-0674(00)00199-X, 11248555.
50. Guo L, Wei G, Zhu J, Liao W, Leonard WJ, Zhao K, Paul W. IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells. PNAS 2009, 106:13463-13468. 10.1073/pnas.0906988106, 2726336, 19666510.
51. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 1998, 18:2545-52. 110634, 9566874.
52. Pedranzini L, Leitch A, Bromberg J. Stat3 is required for the development of skin cancer. J Clin Invest 2004, 114:619-22. 514594, 15343379.
53. Devarajan E, Huang S. STAT3 as a central regulator of tumor metastases. Curr Mol Med 2009, 9:626-33. 10.2174/156652409788488720, 19601811.
54. Melnikova VO, Bar-Eli M. Transcriptional control of the melanoma malignant phenotype. Cancer Biol Ther 2008, 7:997-1003. 10.4161/cbt.7.7.6535, 18698165.
55. Wagner KU, Rui H. Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression. J Mammary Gland Biol Neoplasia 2008, 13:93-103. 10.1007/s10911-008-9062-z, 18228120.
56. Tan SH, Nevalainen MT. Signal transducer and activator of transcription 5A/B in prostate and breast cancers. Endocr Relat Cancer 2008, 15:367-90. 10.1677/ERC-08-0013, 18508994.
57. Townsend PA, Cragg MS, Davidson SM, McCormick J, Barry S, Lawrence KM, Knight RA, Hubank M, Chen PL, Latchman DS, Stephanou A. STAT-1 facilitates the ATM activated checkpoint pathway following DNA damage. J Cell Sci 2005, 118:1629-39. 10.1242/jcs.01728, 15784679.
58. Baus D, Nonnenmacher F, Jankowski S, Döring C, Bräutigam C, Frank M, Hansmann ML, Pfitzner E. STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line. Leukemia 2009, 1-9.
59. Soon L, Flechner L, Gutkind JS, Wang LH, Baserga R, Pierce JH, Li W. Insulin-like growth factor I synergizes with interleukin 4 for hematopoietic cell proliferation independent of insulin receptor substrate expression. Mol Cell Biol 1999, 19:3816-28. 84225, 10207105.
60. Kriebel P, Patel BK, Nelson SA, Grusby MJ, LaRochelle WJ. Consequences of Stat6 deletion on Sis/PDGF- and IL-4-induced proliferation and transcriptional activation in murine fibroblasts. Oncogene 1999, 18:7294-302. 10.1038/sj.onc.1203148, 10602484.
61. Baetta R, Soma M, De-Fraja C, Comparato C, Terruzi C, Magrassi L, Cattaneo E. Upregulation and activation of Stat6 precede vascular smooth muscle cell proliferation in carotid artery injury model. Arterioscler Thromb Vasc Biol 2000, 20:931-9.
62. Das S, Roth CP, Wasson LM, Vishwanatha JK. Signal transducer and activator of transcription -6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. Prostate 2007, 67:1550-64. 10.1002/pros.20640, 17705178.
63. Wang FQ, Fisher J, Fishman DA. MMP-1-PAR1 axis mediates LPA-induced epithelial ovarian cancer (EOC) invasion. Gynecol Oncol 2011, 120:247-55. 10.1016/j.ygyno.2010.10.032, 21093894.
64. Amos S, Redpath GT, Dipierro CG, Carpenter JE, Hussaini IM. Epidermal growth factor receptor-mediated regulation of urokinase plasminogen activator expression and glioblastoma invasion via C-SRC/MAPK/AP-1 signaling pathways. J Neuropathol Exp Neurol 2010, 69:582-92. 10.1097/NEN.0b013e3181e008fe, 20467333.
65. Takahashi S, Yamada-Okabe H, Hamada K, Ohta S, Kawase T, Yoshida K, Toda M. Downregulation of uPARAP mediates cytoskeletal rearrangements and decreases invasion and migration properties in glioma cells. J Neurooncol 2010,
66. Pei D. Matrix metalloproteinases target protease-activated receptors on the tumor cell surface. Cancer Cell 2005, 7:207-8. 10.1016/j.ccr.2005.02.011, 15766657.
67. Cortez MA, Nicoloso MS, Shimizu M, Rossi S, Gopisetty G, Molina JR, Carlotti C, Tirapelli D, Neder L, Brassesco MS, Scrideli CA, Tone LG, Georgescu MM, Zhang W, Puduvalli V, Calin GA. miR-29b and miR-125a regulate podoplanin and suppress invasion in glioblastoma. Genes Chromosomes Cancer 2010, 49:981-90. 10.1002/gcc.20808, 20665731.
68. Wurster AL, Rodgers VL, White MF, Rothstein TL, Grusby MJ. Interleukin-4-mediated protection of primary B cells from apoptosis through Stat6-dependent up-regulation of Bcl-xL. J Biol Chem 2002, 277:27169-75. 10.1074/jbc.M201207200, 12023955.
69. Ostrand-Rosenberg S, Clements VK, Terabe M, Park JM, Berzofsky JA, Dissanayake SK. Resistance to Metastatic Disease in STAT6-Deficient Mice Requires Hemopoietic and Nonhemopoietic Cells and Is IFN-γ Dependent. The Journal of Immunology 2002, 169:5796-5804.
70. Sinha P, Clements VK, Miller S, Ostrand-Rosenberg S. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol Immunother 2005, 54:1137-1142. 10.1007/s00262-005-0703-4, 15877228.
71. Ostrand-Rosenberg S, Grusby MJ, Clements VK. Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. The Journal of Immunology 2000, 165:6015-19.
72. Jensen SM, Meijer SL, Kurt RA, Urba WJ, Hu HM, Fox BA. Regression of a mammary adenocarcinoma in STAT6-/- mice is dependent on the presence of STAT6-reactive T cells. The Journal of Immunology 2003, 170:2014-21.
73. Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, Carbone DP, Paul WE, Berzofsky JA. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nature Immunology 2000, 1:515-520. 10.1038/82771, 11101874.
74. Kacha AK, Fallarino F, Markiewicz MA, Gajewski TF. Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. The Journal of Immunology 2000, 165:6024-28.
75. Wheeler CJ, Black KL. DCVax-Brain and DC vaccines in the treatment of GBM. Expert Opin Investig Drugs 2009, 18:509-519. 10.1517/13543780902841951, 19335279.
76. Yamanaka R. Cell- and peptide-based immunotherapeutic approaches for glioma. Trends in Molecular Medicine 2008, 14:228-235. 10.1016/j.molmed.2008.03.003, 18403264.